Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

D2C7 IT

Next Previous
Drug Profile

D2C7 IT

Alternative Names: D2C7; D2C7-Immunotoxin; D2C7-IT

Latest Information Update: 28 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Duke University Medical Center; Istari Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Drug conjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Peptide elongation factor 2 inhibitors; Protein biosynthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma

Most Recent Events

  • 28 Jun 2026 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Late-stage disease, Recurrent) in USA (Intratumoural, Infusion)
  • 17 Jun 2024 Phase-I development is ongoing in USA (NCT06455605)
  • 12 Jun 2024 Duke University in collaboration with Rockefeller University plans a phase I/II trial for Glioma (Combination therapy, Recurrent, Late-stage disease) in USA (Intratumoral, Infusion) in September 2024 (NCT06455605)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top